Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Rivaroxaban in Valvular Atrial Fibrillation — a Critical Appraisal of the INVICTUS Trial ; day:25 ; month:5 ; year:2023 ; pages:1-3
Cardiovascular drugs and therapy ; (25.5.2023), 1-3
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10557-023-07470-z
- URN
-
urn:nbn:de:101:1-2023091013110224475926
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hammer, Andreas
- Niessner, Alexander
- Sulzgruber, Patrick
- SpringerLink (Online service)
Other Objects (12)
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
Persistent or permanent atrial fibrillation is associated with severe cardioembolic stroke in patients with non-valvular atrial fibrillation
Initial rivaroxaban dosing in patients with atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Cryoablation in persistent atrial fibrillation – a critical appraisal
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation